{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:10:10Z","timestamp":1759734610681,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.prp.2021.153689","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T01:53:00Z","timestamp":1637545980000},"page":"153689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1\/PD-L1 axis"],"prefix":"10.1016","volume":"229","author":[{"given":"Niklas","family":"Wrede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Vollbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Capper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"von Laffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Jurmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2021.153689_bib1","first-page":"739","article-title":"Primary mucosal melanomas: a comprehensive review","volume":"5","author":"Mihajlovic","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.prp.2021.153689_bib2","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2021.153689_bib3","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/sj.onc.1206444","article-title":"Melanoma etiology: where are we?","volume":"22","author":"Tucker","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2021.153689_bib4","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2021.153689_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/path.4204","article-title":"Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma","volume":"230","author":"Furney","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2021.153689_bib6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2014.03.031","article-title":"Update on primary mucosal melanoma","volume":"71","author":"Tacastacas","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.prp.2021.153689_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.prp.2021.153689_bib8","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann. Oncol. . J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.prp.2021.153689_bib9","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/onc.2016.486","article-title":"Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK\/PI3K inhibition or MEK\/CDK4\/6 inhibition","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2021.153689_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/bjc.2013.373","article-title":"KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases","volume":"109","author":"Zebary","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2021.153689_bib11","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin. Cancer Res. . J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.prp.2021.153689_bib12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6602529","article-title":"Lack of clinical efficacy of imatinib in metastatic melanoma","volume":"92","author":"Ugurel","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2021.153689_bib13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/cncr.21834","article-title":"Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy","volume":"106","author":"Wyman","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2021.153689_bib14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2021.153689_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2013.09.007","article-title":"Efficacy and safety of ipilimumab 3mg\/kg in patients with pretreated, metastatic, mucosal melanoma","volume":"50","author":"Del Vecchio","year":"2014","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.prp.2021.153689_bib16","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2021.153689_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/mmt-2017-0014","article-title":"Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma","volume":"4","author":"Kuo","year":"2017","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.prp.2021.153689_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/030098589803500601","article-title":"The cell cycle: a review","volume":"35","author":"Schafer","year":"1998","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.prp.2021.153689_bib19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.prp.2021.153689_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.tig.2006.06.007","article-title":"Gene amplification in cancer","volume":"22","author":"Albertson","year":"2006","journal-title":"Trends Genet"},{"key":"10.1016\/j.prp.2021.153689_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12967-019-1987-z","article-title":"Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy","volume":"17","author":"Xu","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2021.153689_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/mr.55.3.451-458.1991","article-title":"DNA methylation and gene expression","volume":"55","author":"Razin","year":"1991","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.prp.2021.153689_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/pcmr.12745","article-title":"PD\u2010L1 methylation regulates PD\u2010L1 expression and is associated with melanoma survival","volume":"32","author":"Micevic","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.prp.2021.153689_bib24","first-page":"5808","article-title":"Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location\u2010dependent patterns of genetic and epigenetic alterations","author":"Jurmeister","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2021.153689_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2021.153689_bib26","unstructured":"A. Kassambara, ggcorrplot: Visualization of a Correlation Matrix using \u201cggplot2,\u201d 2019. \u3008https:\/\/CRAN.R-project.org\/package=ggcorrplot\u3009 (accessed 15 January 2021)."},{"key":"10.1016\/j.prp.2021.153689_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jop.12235","article-title":"Immunohistochemical profile of oral mucosal and head and neck cutaneous melanoma","volume":"44","author":"Alaeddini","year":"2015","journal-title":"J. Oral. Pathol. Med."},{"key":"10.1016\/j.prp.2021.153689_bib28","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s13277-012-0480-6","article-title":"The role of CCND1 alterations during the progression of cutaneous malignant melanoma","volume":"33","author":"V\u00edzkeleti","year":"2012","journal-title":"Tumor Biol."},{"key":"10.1016\/j.prp.2021.153689_bib29","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.humpath.2013.01.025","article-title":"Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations","volume":"44","author":"Chraybi","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2021.153689_bib30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hed.23079","article-title":"Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases","volume":"35","author":"Turri\u2013Zanoni","year":"2013","journal-title":"Head. Neck"},{"key":"10.1016\/j.prp.2021.153689_bib31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/375506a0","article-title":"Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition","volume":"375","author":"Koh","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.prp.2021.153689_bib32","first-page":"4868","article-title":"CDKN2A\/p16 Is Inactivated in Most Melanoma Cell Lines","volume":"57","author":"Castellano","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2021.153689_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12967-019-1987-z","article-title":"Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy","volume":"17","author":"Xu","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2021.153689_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrg2936","article-title":"Gene silencing by microRNAs: contributions of translational repression and mRNA decay","volume":"12","author":"Huntzinger","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.prp.2021.153689_bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/CMR.0000000000000197","article-title":"Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck","volume":"25","author":"Thierauf","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.prp.2021.153689_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40425-018-0344-8","article-title":"Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden","volume":"6","author":"Morrison","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2021.153689_bib37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2021.153689_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/15384047.2018.1423919","article-title":"PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer","volume":"19","author":"Ren","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.prp.2021.153689_bib39","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/modpathol.2016.139","article-title":"Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma","volume":"29","author":"Lee","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2021.153689_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.prp.2021.153689_bib41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033821003502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033821003502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:48:07Z","timestamp":1759733287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033821003502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"alternative-id":["S0344033821003502"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2021.153689","relation":{},"ISSN":["0344-0338"],"issn-type":[{"type":"print","value":"0344-0338"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1\/PD-L1 axis","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2021.153689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153689"}}